These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31952663)

  • 1. HTA Around the World: Broadening Our Understanding of Cross-Country Differences.
    Torbica A
    Value Health; 2020 Jan; 23(1):1-2. PubMed ID: 31952663
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of Culture, Values, and Politics in the Implementation of Health Technology Assessment in India: A Commentary.
    Swami S; Srivastava T
    Value Health; 2020 Jan; 23(1):39-42. PubMed ID: 31952672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations.
    Vreman RA; Mantel-Teeuwisse AK; Hövels AM; Leufkens HGM; Goettsch WG
    Value Health; 2020 Jan; 23(1):10-16. PubMed ID: 31952664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Emerging Social Science Literature on Health Technology Assessment: A Narrative Review.
    Löblová O; Trayanov T; Csanádi M; Ozierański P
    Value Health; 2020 Jan; 23(1):3-9. PubMed ID: 31952670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formal Implementation of Cost-Effectiveness Evaluations in Japan: A Unique Health Technology Assessment System.
    Hasegawa M; Komoto S; Shiroiwa T; Fukuda T
    Value Health; 2020 Jan; 23(1):43-51. PubMed ID: 31952673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do Social Values and Institutional Context Shape the Use of Economic Evaluation in Reimbursement Decisions? An Empirical Analysis.
    Torbica A; Fornaro G; Tarricone R; Drummond MF
    Value Health; 2020 Jan; 23(1):17-24. PubMed ID: 31952668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increasing the Legitimacy of Tough Choices in Healthcare Reimbursement: Approach and Results of a Citizen Forum in The Netherlands.
    Bijlmakers L; Jansen M; Boer B; van Dijk W; Groenewoud S; Zwaap J; Helderman JK; van Exel J; Baltussen R
    Value Health; 2020 Jan; 23(1):32-38. PubMed ID: 31952671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'The problem is small enough, the problem is big enough': a qualitative study of health technology assessment and public policy on drug funding decisions for children.
    Denburg AE; Giacomini M; Ungar WJ; Abelson J
    Int J Equity Health; 2020 Mar; 19(1):45. PubMed ID: 32228588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disinvestments in practice: overcoming resistance to change through a sociotechnical approach with local stakeholders.
    Airoldi M
    J Health Polit Policy Law; 2013 Dec; 38(6):1149-71. PubMed ID: 23974471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of cost-effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritis.
    Iannazzo S; De Francesco M; Gomez-Ulloa D; Benucci M
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):455-68. PubMed ID: 23977974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health technology assessment and policy from the economic perspective.
    Rutten F
    Int J Technol Assess Health Care; 2004; 20(1):67-70. PubMed ID: 15176179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Evaluation of Systemic Treatments for Advanced Melanoma: A Systematic Review.
    Gorry C; McCullagh L; Barry M
    Value Health; 2020 Jan; 23(1):52-60. PubMed ID: 31952674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health technology assessment (HTA): ethical aspects.
    Sacchini D; Virdis A; Refolo P; Pennacchini M; de Paula IC
    Med Health Care Philos; 2009 Nov; 12(4):453-7. PubMed ID: 19507050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Values and evidence colliding: health technology assessment in child health.
    Ungar WJ; Prosser LA; Burnett HF
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):417-9. PubMed ID: 23977967
    [No Abstract]   [Full Text] [Related]  

  • 15. Healthcare rationing. Decision time.
    Moore A
    Health Serv J; 2011 May; 121(6255):22-3. PubMed ID: 21682223
    [No Abstract]   [Full Text] [Related]  

  • 16. A determination of topics for health technology assessment in Thailand: making decision makers involved.
    Lertpitakpong C; Chaikledkaew U; Thavorncharoensap M; Tantivess S; Praditsitthikorn N; Youngkong S; Yothasamut J; Udomsuk K; Sinthitichai K; Teerawattananon Y
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S100-9. PubMed ID: 19253492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic Evaluation for Pricing and Reimbursement of New Drugs in Spain: Fable or Desideratum?
    Oliva-Moreno J; Puig-Junoy J; Trapero-Bertran M; Epstein D; Pinyol C; Sacristán JA
    Value Health; 2020 Jan; 23(1):25-31. PubMed ID: 31952669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales.
    Birch S; Gafni A
    Health Econ; 2002 Apr; 11(3):185-91. PubMed ID: 11921316
    [No Abstract]   [Full Text] [Related]  

  • 19. HTA Implementation Roadmap in Central and Eastern European Countries.
    Kaló Z; Gheorghe A; Huic M; Csanádi M; Kristensen FB
    Health Econ; 2016 Feb; 25 Suppl 1(Suppl Suppl 1):179-92. PubMed ID: 26763688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decision Making for Healthcare Resource Allocation: Joint v. Separate Decisions on Interacting Interventions.
    Dakin H; Gray A
    Med Decis Making; 2018 May; 38(4):476-486. PubMed ID: 29683792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.